- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.
Technology platforms that span the entire drug discovery to manufacturing spectrum.
A WuXi Biologics subsidiary, greatly simplifies bioconjugate development and manufacturing.
Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from concept to commercialization.
Providing extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories.
E. coli and yeast based expression systems, process development and cGMP manufacturing platform
World-class quality systems approved by the U.S. FDA, EMA and NMPA.
Viral vector based vaccine and therapeutic virus development and cGMP manufacturing platform.
Total estimated capacity for biopharmaceutical production in China, Ireland, the U.S., Germany and Singapore to exceed 430,000 liters by 2024.